Flerie AB (STU:1NP1) Debt-to-Asset : 0.00 (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Flerie AB Debt-to-Asset?

Flerie AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was €0.05 Mil. Flerie AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was €0.03 Mil. Flerie AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2025 was €361.30 Mil. Flerie AB's debt to asset for the quarter that ended in Mar. 2025 was 0.00.

Flerie AB Debt-to-Asset Historical Data

The historical data trend for Flerie AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Flerie AB Debt-to-Asset Chart

Flerie AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.04

0.01

Flerie AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Asset	Get a 7-Day Free Trial															0.01	-	-	-	-

Competitive Comparison of Flerie AB's Debt-to-Asset

For the Biotechnology subindustry, Flerie AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Flerie AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Flerie AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Flerie AB's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Flerie AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Flerie AB's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.035	+	0.035)	/	367.16
	=	0.00

Flerie AB's Debt-to-Asset for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.046	+	0.027)	/	361.298
	=	0.00

Flerie AB (STU:1NP1) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Flerie AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Flerie AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Flerie AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Flerie AB (STU:1NP1) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

FLERIE:Sweden

Address

Skeppsbron 16, Stockholm, SWE, 111 30

Website

https://www.flerie.com/en

Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations.

Flerie AB Headlines

No Headlines